📊 ADVB Key Takeaways
Is Advanced Biomed Inc. (ADVB) a Good Investment?
Advanced Biomed reports strong accounting returns (ROE 65%, ROA 56.2%) and a fortress balance sheet, but negative operating cash flow of -1.4M despite 6.0M net income signals critical quality-of-earnings concerns. Deteriorating profitability (-17.1% net income YoY, -14.3% EPS YoY) combined with undisclosed revenue and minimal insider activity raises red flags about operational sustainability.
Advanced Biomed shows an unusually strong balance sheet for its size, with high liquidity, minimal liabilities, and no leverage. However, earnings quality appears weak because reported net income is positive while operating cash flow and free cash flow are negative, and profit declined year over year. The combination suggests financial stability in the near term, but limited visibility into sustainable operating performance.
Advanced Biomed Inc. Key Strengths (ADVB)
- Exceptional ROE (65%) and ROA (56.2%) demonstrate high capital efficiency
- Zero debt (Debt/Equity 0.00x) with pristine balance sheet and 7.38x current ratio
- Strong absolute profitability: 6.3M operating income, 6.0M net income, positive EPS
- Very strong liquidity with current and quick ratios of 8.56x
- Debt-free balance sheet with only $1.37M of liabilities against $9.48M of equity
- Positive net income and high reported ROE/ROA indicate capital-light profitability
ADVB Stock Risks: Advanced Biomed Inc. Investment Risks
- Negative operating cash flow (-1.4M) contradicts positive net income—major quality-of-earnings red flag suggesting non-cash accounting gains or working capital deterioration
- Profitability declining sharply (Net Income -17.1% YoY, EPS -14.3% YoY) indicating deteriorating fundamentals
- Revenue data not disclosed—inability to assess gross margins, operating leverage, or true revenue-to-profit relationship for medical lab services firm
- Negative operating cash flow and free cash flow raise concerns about earnings quality and cash conversion
- Net income declined 17.1% year over year, signaling weakening profitability
- Missing revenue and margin data reduces visibility into the durability and source of earnings
Key Metrics to Watch
- Operating cash flow trend—must turn positive to validate profit quality
- Quarterly revenue and gross margin disclosure—critical for sector analysis
- YoY profitability trajectory—declining trend must stabilize or reverse
- Operating cash flow relative to net income
- Revenue growth and operating margin consistency
Advanced Biomed Inc. (ADVB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.38x current ratio provides a solid financial cushion.
ADVB Profit Margin, ROE & Profitability Analysis
ADVB vs Healthcare Sector: How Advanced Biomed Inc. Compares
How Advanced Biomed Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Advanced Biomed Inc. Stock Overvalued? ADVB Valuation Analysis 2026
Based on fundamental analysis, Advanced Biomed Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Advanced Biomed Inc. Balance Sheet: ADVB Debt, Cash & Liquidity
ADVB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Advanced Biomed Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.14 indicates the company is currently unprofitable.
ADVB Revenue Growth, EPS Growth & YoY Performance
Advanced Biomed Inc. Dividends, Buybacks & Capital Allocation
ADVB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Advanced Biomed Inc. (CIK: 0001941029)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ADVB
What is the AI rating for ADVB?
Advanced Biomed Inc. (ADVB) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 67% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ADVB's key strengths?
Claude: Exceptional ROE (65%) and ROA (56.2%) demonstrate high capital efficiency. Zero debt (Debt/Equity 0.00x) with pristine balance sheet and 7.38x current ratio. ChatGPT: Very strong liquidity with current and quick ratios of 8.56x. Debt-free balance sheet with only $1.37M of liabilities against $9.48M of equity.
What are the risks of investing in ADVB?
Claude: Negative operating cash flow (-1.4M) contradicts positive net income—major quality-of-earnings red flag suggesting non-cash accounting gains or working capital deterioration. Profitability declining sharply (Net Income -17.1% YoY, EPS -14.3% YoY) indicating deteriorating fundamentals. ChatGPT: Negative operating cash flow and free cash flow raise concerns about earnings quality and cash conversion. Net income declined 17.1% year over year, signaling weakening profitability.
What is ADVB's revenue and growth?
Advanced Biomed Inc. reported revenue of N/A.
Does ADVB pay dividends?
Advanced Biomed Inc. does not currently pay dividends.
Where can I find ADVB SEC filings?
Official SEC filings for Advanced Biomed Inc. (CIK: 0001941029) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ADVB's EPS?
Advanced Biomed Inc. has a diluted EPS of $5.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ADVB's fundamental grade?
Based on our AI fundamental analysis in June 2026, Advanced Biomed Inc. has a C grade with 67% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ADVB stock overvalued or undervalued?
Valuation metrics for ADVB: ROE of 65.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is ADVB's AI grade for 2026?
Our dual AI analysis gives Advanced Biomed Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ADVB's free cash flow?
Advanced Biomed Inc.'s operating cash flow is $-1.4M, with capital expenditures of $15.9K.
How does ADVB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE 65.0% (avg: 15%), current ratio 7.38 (avg: 2).
Why is ADVB's return on equity (ROE) so high?
Advanced Biomed Inc. has a return on equity of 65.0%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity.